Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605618073> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2605618073 abstract "TPS8617 Background: PI3K-delta is critical for activation, proliferation and survival of B cells and plays a role in homing and retention in lymphoid tissues. PI3Kδ signaling is hyperactive in many B-cell malignancies. Idelalisib is a first-in-class, targeted, highly selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues (Lannutti et al, 2011). Phase 1 trials demonstrated that idelalisib is highly active in pts with heavily pretreated iNHL: pts experienced reductions in disease-associated chemokines, profound and rapid reductions in lymphadenopathy, and durable clinical benefit with acceptable safety profile (de Vos et al, 2011). Methods: 375 pts with previously treated iNHL, who have measurable lymphadenopathy, have received prior anti-CD20-antibody-containing therapy, and who have iNHL that is not refractory to rituximab (R) are randomized in a 2:1 ratio into Arm A or Arm B. In Arm A, pts receive idelalisib at 150 mg BID continuously + R at 375 mg/m 2 (weekly x 4 then every 8 weeks x 4). In Arm B, pts receive placebo BID instead of idelalisib. Stratification factors include tumor type (follicular lymphoma vs others), tumor burden (high vs low), and time since completion of last prior therapy for iNHL (<18 months vs ≥18 months). The primary endpoint is PFS and key secondary endpoints include ORR, lymph node response rate, CR rate, and OS. This is an event-driven trial and primary endpoint evaluation will be based on independent central review. For the primary efficacy analysis, the difference in PFS between the treatment arms will be assessed in the ITT analysis set using Kaplan-Meier methods and the stratified log-rank test. The study opened for enrollment in Dec 2012 (NCT01732913). Clinical trial information: NCT01732913." @default.
- W2605618073 created "2017-04-28" @default.
- W2605618073 creator A5012989377 @default.
- W2605618073 creator A5013293066 @default.
- W2605618073 creator A5016136114 @default.
- W2605618073 creator A5016764336 @default.
- W2605618073 creator A5027453053 @default.
- W2605618073 creator A5037882455 @default.
- W2605618073 creator A5042317118 @default.
- W2605618073 creator A5048838398 @default.
- W2605618073 creator A5064196229 @default.
- W2605618073 creator A5065902991 @default.
- W2605618073 creator A5069054551 @default.
- W2605618073 creator A5069477380 @default.
- W2605618073 creator A5091882595 @default.
- W2605618073 date "2013-05-20" @default.
- W2605618073 modified "2023-10-07" @default.
- W2605618073 title "A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL)." @default.
- W2605618073 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps8617" @default.
- W2605618073 hasPublicationYear "2013" @default.
- W2605618073 type Work @default.
- W2605618073 sameAs 2605618073 @default.
- W2605618073 citedByCount "2" @default.
- W2605618073 countsByYear W26056180732013 @default.
- W2605618073 countsByYear W26056180732020 @default.
- W2605618073 crossrefType "journal-article" @default.
- W2605618073 hasAuthorship W2605618073A5012989377 @default.
- W2605618073 hasAuthorship W2605618073A5013293066 @default.
- W2605618073 hasAuthorship W2605618073A5016136114 @default.
- W2605618073 hasAuthorship W2605618073A5016764336 @default.
- W2605618073 hasAuthorship W2605618073A5027453053 @default.
- W2605618073 hasAuthorship W2605618073A5037882455 @default.
- W2605618073 hasAuthorship W2605618073A5042317118 @default.
- W2605618073 hasAuthorship W2605618073A5048838398 @default.
- W2605618073 hasAuthorship W2605618073A5064196229 @default.
- W2605618073 hasAuthorship W2605618073A5065902991 @default.
- W2605618073 hasAuthorship W2605618073A5069054551 @default.
- W2605618073 hasAuthorship W2605618073A5069477380 @default.
- W2605618073 hasAuthorship W2605618073A5091882595 @default.
- W2605618073 hasConcept C126322002 @default.
- W2605618073 hasConcept C142724271 @default.
- W2605618073 hasConcept C143998085 @default.
- W2605618073 hasConcept C204787440 @default.
- W2605618073 hasConcept C27081682 @default.
- W2605618073 hasConcept C2777938653 @default.
- W2605618073 hasConcept C2778461978 @default.
- W2605618073 hasConcept C2778714382 @default.
- W2605618073 hasConcept C2779260929 @default.
- W2605618073 hasConcept C2779338263 @default.
- W2605618073 hasConcept C2779878957 @default.
- W2605618073 hasConcept C2780653079 @default.
- W2605618073 hasConcept C31760486 @default.
- W2605618073 hasConcept C535046627 @default.
- W2605618073 hasConcept C71924100 @default.
- W2605618073 hasConceptScore W2605618073C126322002 @default.
- W2605618073 hasConceptScore W2605618073C142724271 @default.
- W2605618073 hasConceptScore W2605618073C143998085 @default.
- W2605618073 hasConceptScore W2605618073C204787440 @default.
- W2605618073 hasConceptScore W2605618073C27081682 @default.
- W2605618073 hasConceptScore W2605618073C2777938653 @default.
- W2605618073 hasConceptScore W2605618073C2778461978 @default.
- W2605618073 hasConceptScore W2605618073C2778714382 @default.
- W2605618073 hasConceptScore W2605618073C2779260929 @default.
- W2605618073 hasConceptScore W2605618073C2779338263 @default.
- W2605618073 hasConceptScore W2605618073C2779878957 @default.
- W2605618073 hasConceptScore W2605618073C2780653079 @default.
- W2605618073 hasConceptScore W2605618073C31760486 @default.
- W2605618073 hasConceptScore W2605618073C535046627 @default.
- W2605618073 hasConceptScore W2605618073C71924100 @default.
- W2605618073 hasLocation W26056180731 @default.
- W2605618073 hasOpenAccess W2605618073 @default.
- W2605618073 hasPrimaryLocation W26056180731 @default.
- W2605618073 hasRelatedWork W1618071166 @default.
- W2605618073 hasRelatedWork W1648818536 @default.
- W2605618073 hasRelatedWork W2050997155 @default.
- W2605618073 hasRelatedWork W2287352866 @default.
- W2605618073 hasRelatedWork W2320320404 @default.
- W2605618073 hasRelatedWork W2410264528 @default.
- W2605618073 hasRelatedWork W2479900433 @default.
- W2605618073 hasRelatedWork W2516115738 @default.
- W2605618073 hasRelatedWork W2535685431 @default.
- W2605618073 hasRelatedWork W2588979001 @default.
- W2605618073 hasRelatedWork W2597467395 @default.
- W2605618073 hasRelatedWork W2597780462 @default.
- W2605618073 hasRelatedWork W2601443433 @default.
- W2605618073 hasRelatedWork W2762543649 @default.
- W2605618073 hasRelatedWork W2800681950 @default.
- W2605618073 hasRelatedWork W2802905910 @default.
- W2605618073 hasRelatedWork W2803079541 @default.
- W2605618073 hasRelatedWork W2889677764 @default.
- W2605618073 hasRelatedWork W2907176888 @default.
- W2605618073 hasRelatedWork W3031511517 @default.
- W2605618073 isParatext "false" @default.
- W2605618073 isRetracted "false" @default.
- W2605618073 magId "2605618073" @default.
- W2605618073 workType "article" @default.